TScan Therapeutics, Inc. (NASDAQ:TCRX) Receives $9.33 Average Price Target from Analysts

Shares of TScan Therapeutics, Inc. (NASDAQ:TCRX) have received a consensus recommendation of “Buy” from the six ratings firms that are covering the stock, MarketBeat.com reports. Six investment analysts have rated the stock with a buy rating. The average 12 month target price among brokers that have covered the stock in the last year is $9.33.

A number of equities analysts recently weighed in on the company. Morgan Stanley reiterated an “overweight” rating and issued a $10.00 price target on shares of TScan Therapeutics in a research report on Friday. Wedbush restated an “outperform” rating and set a $7.00 price objective on shares of TScan Therapeutics in a research report on Wednesday, March 5th. Needham & Company LLC reduced their price target on TScan Therapeutics from $11.00 to $9.00 and set a “buy” rating for the company in a report on Wednesday, March 5th. HC Wainwright reissued a “buy” rating and issued a $15.00 price objective on shares of TScan Therapeutics in a research note on Thursday, March 6th. Finally, Barclays cut their price objective on TScan Therapeutics from $14.00 to $3.00 and set an “overweight” rating on the stock in a research note on Friday, March 7th.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in TCRX. China Universal Asset Management Co. Ltd. bought a new position in TScan Therapeutics in the 4th quarter worth approximately $32,000. Prudential Financial Inc. bought a new position in TScan Therapeutics in the 4th quarter worth approximately $32,000. ProShare Advisors LLC bought a new position in TScan Therapeutics in the 4th quarter worth approximately $40,000. Wells Fargo & Company MN grew its holdings in shares of TScan Therapeutics by 41.1% during the 4th quarter. Wells Fargo & Company MN now owns 19,540 shares of the company’s stock worth $59,000 after purchasing an additional 5,694 shares in the last quarter. Finally, Squarepoint Ops LLC acquired a new stake in shares of TScan Therapeutics during the 4th quarter worth approximately $59,000. 82.83% of the stock is owned by institutional investors.

TScan Therapeutics Price Performance

Shares of TCRX opened at $1.74 on Friday. The firm has a market capitalization of $98.47 million, a price-to-earnings ratio of -1.64 and a beta of 0.91. The company has a debt-to-equity ratio of 0.13, a quick ratio of 9.56 and a current ratio of 9.56. TScan Therapeutics has a one year low of $1.71 and a one year high of $9.69. The stock’s fifty day moving average is $2.28 and its 200-day moving average is $3.85.

TScan Therapeutics (NASDAQ:TCRX) last released its earnings results on Wednesday, March 5th. The company reported ($0.29) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.27) by ($0.02). TScan Therapeutics had a negative return on equity of 58.72% and a negative net margin of 1,188.88%. The firm had revenue of $0.67 million for the quarter, compared to analyst estimates of $1.43 million. Equities analysts anticipate that TScan Therapeutics will post -1.12 EPS for the current year.

About TScan Therapeutics

TScan Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation.